Protalix BioTherapeutics Stock Guidance | AMEX:PLX

Comments

Protalix BioTherapeutics Inc Stock Guidance

PLXAMEX

Trade with Public

$2.30

0.020.88%

At close: Apr 10, 5:00 PM EST

$2.30

N/A

After Hours: Apr 10, 4:00 PM EST

Overview News Earnings OptionsGuidanceAnalyst Ratings Insider Trades Short Interest Stock Report

Protalix BioTherapeutics (PLX) last issued guidance on March 18, 2026 for fiscal year 2026. The company guided revenue in the range of $78.00M - $83.00M for the period.

Latest Guidance Date

Mar 18, 2026

Guidance Period

Full Year 2026

Revenue Guidance Range

$78.00M - $83.00M

Protalix BioTherapeutics Guidance History

Review all historical guidance issued by Protalix BioTherapeutics, including EPS and revenue forecasts across quarterly and annual periods.

Loading calendar...

FAQ

What is the most recent guidance for Protalix BioTherapeutics (PLX)?

The most recent guidance for Protalix BioTherapeutics (PLX) was reported on March 18, 2026 for the fiscal year 2026. Protalix BioTherapeutics forecasted revenue between $78.00M and $83.00M for the period.

What revenue range did Protalix BioTherapeutics (PLX) guide for?

Protalix BioTherapeutics (PLX) guided revenue in the range of $78.00M to $83.00M for the fiscal year 2026.

When did Protalix BioTherapeutics (PLX) last issue guidance?

Protalix BioTherapeutics (PLX) last issued guidance on March 18, 2026 for the fiscal year 2026.

People Also Watch

Atrium Therapeutics Inc

NASDAQ:RNA

$12.71

ProQR Therapeutics NV

Burning Rock Biotech Ltd

NASDAQ:BNR

$16.40

3.50%

Elicio Therapeutics Inc

NASDAQ:ELTX

$10.00

-1.48%

Whitehawk Therapeutics Inc

NASDAQ:WHWK

$3.39

Anika Therapeutics Inc

NASDAQ:ANIK

$15.21

3.05%